Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SLV 306

Known as: SLV-306, SLV306 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Since the discovery of endothelin (ET)-1 in 1988, the main components of the signalling pathway have become established… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
AIMS Inhibition of neutral endopeptidases (NEP) results in a beneficial increase in plasma concentrations of natriuretic peptides… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Diabetic nephropathy is a serious complication of diabetes associated with a poor prognosis which deteriorates to end-stage renal… Expand
Is this relevant?
2004
2004
SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in… Expand
Is this relevant?
Review
2003
Review
2003
SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for… Expand
Is this relevant?